Key Points
2
➤ Prediabetes is highly prevalent in older people, however, interventions to
delay progression from prediabetes to diabetes are especially effective in
this age group.
➤ The prevalence of type 2 diabetes increases as individuals age and
exaggerates the incidence of both microvascular and macrovascular
complications.
➤ Clinicians should perform regular screening for prediabetes and diabetes
in the older population and implement interventions as indicated in this
guideline.
➤ Given the heterogeneity of the health status of older people with diabetes,
the guideline emphasizes shared decision-making and provides a
framework to assist health care providers to individualize treatment goals.
➤ The problems that older individuals with diabetes face, in contrast to
younger people with the disease, include sarcopenia, frailty and cognitive
dysfunction. Such complications can lead to an increased risk of poor
medication adherence, hypoglycemia (from certain medications), falls, and
loss of independence in daily living activities.
➤ The guideline presents evidence for the various effects of diabetes
in the older patients and the relevant therapies for glycemic control,
hyperlipidemia and hypertension.
➤ Guideline recommendations also address common co-morbidities
such as renal impairment, which affects the pharmacokinetics and
pharmacodynamics of specific agents, and concomitant heart disease.
Diagnosis and Prevention
➤ In patients aged 65 years and older without known diabetes, Endocrine
Society (ES) recommends fasting plasma glucose and/or HbA1c screening
to diagnose diabetes or prediabetes. (1|⊕⊕⊕⊕)
Technical Remarks:
▶ The measurement of HbA1c may be inaccurate in some people in this age group
because of comorbidities that can affect the lifespan of red blood cells in the
circulation.
▶ Although the optimal screening frequency for patients whose initial screening test
is normal remains unclear, the writing committee advocates repeat screening every
2 years thereafter.
▶ As with any health screening, the decision about diabetes and prediabetes screening
for an individual patient depends on whether some action will be taken as a result
and the likelihood of benefit. For example, such screening may not be appropriate
for an older patient with end-stage cancer or organ system failure. In these
situations, shared decision-making with the patient is recommended.